TW200745137A - Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors - Google Patents

Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors

Info

Publication number: TW200745137A
Authority: TW; Taiwan
Prior art keywords: carbonitriles; thieno; pyridine; protein kinase; kinase inhibitors
Prior art date: 2005-09-27

Application number

TW095135537A

Other languages

English (en)

Inventor

Diane Harris Boschelli

Derek Cecil Cole

Magda Asselin

Ana Carolina Barrios Sosa

Bi-Qi Wu

Lawrence Nathan Tumey

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-27

Filing date

2006-09-26

Publication date

2007-12-16

2006-09-26 Application filed by Wyeth Corp filed Critical Wyeth Corp

2007-12-16 Publication of TW200745137A publication Critical patent/TW200745137A/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Transplantation (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

TW095135537A 2005-09-27 2006-09-26 Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors TW200745137A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US72082105P	2005-09-27	2005-09-27

Publications (1)

Publication Number	Publication Date
TW200745137A true TW200745137A (en)	2007-12-16

Family

ID=37603099

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095135537A TW200745137A (en)	2005-09-27	2006-09-26	Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors

Country Status (16)

Country	Link
US (1)	US20070082880A1 (zh)
EP (1)	EP1937690A1 (zh)
JP (1)	JP2009511439A (zh)
KR (1)	KR20080059184A (zh)
CN (1)	CN101273047A (zh)
AR (1)	AR056200A1 (zh)
AU (1)	AU2006294726A1 (zh)
BR (1)	BRPI0616758A2 (zh)
CA (1)	CA2623228A1 (zh)
GT (1)	GT200600434A (zh)
NO (1)	NO20081133L (zh)
PE (1)	PE20070619A1 (zh)
RU (1)	RU2008108619A (zh)
TW (1)	TW200745137A (zh)
WO (1)	WO2007038519A1 (zh)
ZA (1)	ZA200802690B (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7276519B2 (en) *	2002-11-25	2007-10-02	Wyeth	Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
TW200821318A (en) *	2006-09-26	2008-05-16	Wyeth Corp	Process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles
US20090118276A1 (en) *	2007-11-02	2009-05-07	Wyeth	Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
EP2512242B8 (en)	2009-12-18	2015-12-09	GlaxoSmithKline Intellectual Property Limited	Novel compounds
EP2611812A1 (en) *	2010-09-01	2013-07-10	Ambit Biosciences Corporation	Thienopyridine and thienopyrimidine compounds and methods of use thereof
AU2011303597A1 (en)	2010-09-17	2013-04-11	Purdue Pharma L.P.	Pyridine compounds and the uses thereof
WO2012136120A1 (zh) *	2011-04-02	2012-10-11	中国人民解放军军事医学科学院毒物药物研究所	芳基丙烯酰胺化合物及其用于制备免疫抑制剂的用途
EP3295940A1 (en) *	2012-04-16	2018-03-21	Case Western Reserve University	Compositions and methods of modulating 15-pgdh activity
US9801863B2 (en)	2012-04-16	2017-10-31	Case Western Reserve University	Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
US9789116B2 (en)	2013-10-15	2017-10-17	Case Western Reserve University	Compositions and methods of modulating short-chain dehydrogenase activity
BR112018068066B1 (pt) *	2016-03-11	2023-11-28	Ac Immune Sa	Compostos bicíclicos e seu uso, composição diagnóstica e farmacêutica, misturas, métodos de coleção de dados para diagnóstico, para determinar uma predisposição a, para monitorar transtorno residual e para prever a capacidade de resposta de um paciente sofrendo de transtorno ou anormalidade associado com agregados de alfa-sinucleína, métodos para determinar a quantidade de agregados de alfa-sinucleína e para preparar um composto, kit teste e kit para preparar uma preparação radio farmacêutica
WO2018102552A1 (en)	2016-11-30	2018-06-07	Case Western Reserve University	Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof
JP2020514323A (ja)	2017-02-06	2020-05-21	ケースウエスタンリザーブユニバーシティ	短鎖デヒドロゲナーゼ活性を調節する組成物と方法
EA202191422A1 (ru)	2018-11-21	2021-10-21	Кейс Вестерн Ризерв Юниверсити	Композиции и способы модулирования активности короткоцепочечной дегидрогеназы
EP3897630B1 (en) *	2018-12-21	2024-01-10	Celgene Corporation	Thienopyridine inhibitors of ripk2
EP4384510A4 (en) *	2021-08-10	2025-08-06	Jacobio Pharmaceuticals Co Ltd	COMPOUNDS TARGETING A P53 MUTANT
CN114957280B (zh) *	2021-12-31	2024-09-17	成都赜灵生物医药科技有限公司	噻吩[2,3-d]嘧啶衍生物及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA782648B (en) *	1977-05-23	1979-06-27	Ici Australia Ltd	The prevention,control or eradication of infestations of ixodid ticks
HUP0100287A3 (en) *	1997-11-11	2003-04-28	Pfizer Prod Inc	Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US5948911A (en) *	1998-11-20	1999-09-07	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives
GB9906566D0 (en) *	1999-03-23	1999-05-19	Zeneca Ltd	Chemical compounds
KR20020029419A (ko) *	1999-07-07	2002-04-18	다비드 에 질레스	퀴나졸린 유도체
WO2001066099A2 (en) *	2000-03-06	2001-09-13	Astrazeneca Ab	Use of quinazoline derivatives as angiogenesis inhibitors
DE60106022T2 (de) *	2000-06-06	2006-03-09	Pfizer Products Inc., Groton	Thiophenverbindungen zur verwendung als antikrebsmittel
US20020004511A1 (en) *	2000-06-28	2002-01-10	Luzzio Michael Joseph	Thiophene derivatives useful as anticancer agents
US6995171B2 (en) *	2001-06-21	2006-02-07	Agouron Pharmaceuticals, Inc.	Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
JP4364120B2 (ja) *	2002-06-06	2009-11-11	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	置換３−アミノ−チエノ［２，３−ｂ］ピリジン−２−カルボン酸アミド化合物、その製造方法及び使用
CL2003002287A1 (es) *	2002-11-25	2005-01-14	Wyeth Corp	COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
US7276519B2 (en) *	2002-11-25	2007-10-02	Wyeth	Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
US7674907B2 (en) *	2004-07-23	2010-03-09	Amgen Inc.	Furanopyridine derivatives and methods of use
JP2008513463A (ja) *	2004-09-15	2008-05-01	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	チアゾロピリジンキナーゼ阻害剤
KR101378716B1 (ko) *	2005-05-20	2014-04-10	메틸진 인코포레이티드	Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제

2006
- 2006-09-25 PE PE2006001155A patent/PE20070619A1/es not_active Application Discontinuation
- 2006-09-25 AR ARP060104166A patent/AR056200A1/es unknown
- 2006-09-26 TW TW095135537A patent/TW200745137A/zh unknown
- 2006-09-27 EP EP06804164A patent/EP1937690A1/en not_active Withdrawn
- 2006-09-27 US US11/527,996 patent/US20070082880A1/en not_active Abandoned
- 2006-09-27 KR KR1020087008455A patent/KR20080059184A/ko not_active Withdrawn
- 2006-09-27 CA CA002623228A patent/CA2623228A1/en not_active Abandoned
- 2006-09-27 BR BRPI0616758-6A patent/BRPI0616758A2/pt not_active IP Right Cessation
- 2006-09-27 WO PCT/US2006/037502 patent/WO2007038519A1/en not_active Ceased
- 2006-09-27 GT GT200600434A patent/GT200600434A/es unknown
- 2006-09-27 CN CNA2006800357351A patent/CN101273047A/zh active Pending
- 2006-09-27 AU AU2006294726A patent/AU2006294726A1/en not_active Abandoned
- 2006-09-27 RU RU2008108619/04A patent/RU2008108619A/ru not_active Application Discontinuation
- 2006-09-27 JP JP2008533522A patent/JP2009511439A/ja not_active Withdrawn
2008
- 2008-03-04 NO NO20081133A patent/NO20081133L/no not_active Application Discontinuation
- 2008-03-26 ZA ZA200802690A patent/ZA200802690B/xx unknown

Also Published As

Publication number	Publication date
CA2623228A1 (en)	2007-04-05
JP2009511439A (ja)	2009-03-19
AR056200A1 (es)	2007-09-26
EP1937690A1 (en)	2008-07-02
BRPI0616758A2 (pt)	2011-06-28
ZA200802690B (en)	2009-08-26
KR20080059184A (ko)	2008-06-26
US20070082880A1 (en)	2007-04-12
RU2008108619A (ru)	2009-11-10
NO20081133L (no)	2008-04-25
WO2007038519A1 (en)	2007-04-05
GT200600434A (es)	2007-05-28
CN101273047A (zh)	2008-09-24
PE20070619A1 (es)	2007-07-02
AU2006294726A1 (en)	2007-04-05

Publication	Publication Date	Title
NO20081133L (no)	2008-04-25	Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer
MX2009010728A (es)	2009-10-26	Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora.
TW200740815A (en)	2007-11-01	P38 MAP kinase inhibitors and methods for using the same
GEP20105054B (en)	2010-07-26	Imidazoquinolines as lipid kinase inhibitors
MY152283A (en)	2014-09-15	Polo-like kinase inhibitirs
MY169791A (en)	2019-05-15	Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
WO2007095223A3 (en)	2010-06-24	Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
WO2005113515A8 (de)	2006-11-02	Pyrimidine als plk inhibitoren
ZA200707342B (en)	2009-03-25	Pyrrolopyrimidines useful as inhibitors of protein kinase
GEP20084367B (en)	2008-05-13	Diazepinoindole derivatives as kinase inhibitors
IL187586A0 (en)	2008-03-20	Method for producing dihydroquinazolines
IL195238A0 (en)	2009-08-03	Pyrazolo [1,5-a]pyrimidines as cdk inhibitors
MX2011012353A (es)	2011-12-14	Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
MX2010006748A (es)	2010-08-18	Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
CA2603830A1 (en)	2006-11-30	PYRIDINE [2,3-B] PYRAZINONES
TW200716589A (en)	2007-05-01	Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]-oxepino [4,5-c] pyrrole
GEP20135780B (en)	2013-03-11	Novel pyrazolo [3,4-d] pyrimidine derivatives as anti-cancer agents
TW200630374A (en)	2006-09-01	Thiazolyldihydroindazoles
WO2007059905A3 (en)	2007-08-02	Thienopyrimidines treating inflammatory diseases
WO2007097981A3 (en)	2007-10-25	Alpha carbolines and uses thereof
MX2009004771A (es)	2009-06-17	Compuestos heteroaril triciclicos utiles como inhibidores de janus cinasa.
MY150747A (en)	2014-02-28	Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
MX2007010045A (es)	2007-10-02	Pirazolopirimidinas.
WO2005076990A3 (en)	2005-11-24	Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
MX2008013724A (es)	2009-06-19	Proceso para la preparacion de formas polimorficas de hidrogeno sulfato clopidrogel.